Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Tremendous progress over the past decade has been made in managing chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.
A novel PROTAC-based BCL-2/BCL-XL degrader was able to cause cell death in laboratory models of venetoclax-resistant chronic lymphocytic leukemia (CLL).
Pirtobrutinib was generally well-tolerated, and most patients did not experience high-grade recurrence of the adverse event that led to discontinuation of the prior covalent Bruton tyrosine kinase inhibitor (BTKi). Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who could not tolerate previous covalent BTKi treatment.
MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.
Evusheld may not have been our perfect get-out-of-jail-free card, like in the game of Monopoly, during the last year. Still, it did provide a similar and perhaps superior degree of safety for the CLL / SLL community compared to that afforded by vaccinations in our friends with a normal immune systems.
CLL Society’s COVID-19 Update for the Week of November 28th, 2022: Here is your weekly summary of what has been happening this past week in the United States. Keep in mind, data is always going to be delayed/underreported when there is a holiday weekend due to government offices being closed. But we are still going to provide the latest information available to us.
What follows is our patient-friendly summary of this research.: BMF-219, an irreversible menin inhibitor that demonstrated strong preclinical activity against chronic lymphocytic leukemia or CLL patients’ specimens, including those with high-risk markers.
What follows is just my opinion. Data are thin in many areas, but there are also some areas of solid research to guide us.
One click to our most popular content.
